GRAPPA Psoriatic Arthritis Recommendations 2021 - Novartis Translations

GRAPPA PsA Pocket Guide (English)

GRAPPA 2021 PsA Pocket Guide courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1476166

Contents of this Issue

Navigation

Page 2 of 11

3 Treatment Overarching Principles ➤ These recommendations, which include the most current data concerning the optimal therapeutic approaches to PsA, present contextual considerations to empower shared decision-making. ➤ The ultimate goals of therapy for all patients with PsA are: • To achieve the lowest possible level of disease activity in all domains of disease. As definitions of remission and low or minimal disease activity become accepted, these will be included in the goal • To optimize functional status, improve quality of life and wellbeing, and prevent structural damage to the greatest extent possible • To avoid or minimize complications, both from untreated active disease and from therapy ➤ Assessment of patients with PsA requires consideration of all disease domains, including peripheral arthritis, axial disease, enthesitis, dactylitis, skin psoriasis, psoriatic nail disease, uveitis and IBD. The impact of disease on pain, function, quality of life and structural damage should be examined. ➤ Clinical assessment ideally includes patient-reported measures with a comprehensive history and physical examination, often supplemented by laboratory tests and imaging techniques (for example, X-ray, ultrasound or MRI). The most widely accepted metrics that have been validated for PsA should be utilized whenever possible. ➤ Comorbidities and related conditions should be considered and their impact on the approach to the condition and its treatment addressed appropriately. Such conditions include obesity, metabolic syndrome, cardiovascular disease, depression and anxiety, liver disease (for example, non-alcoholic fatty liver disease), chronic infections, malignancy, bone health (for example, osteoporosis), central sensitization (for example, fibromyalgia) and reproductive health. Multidisciplinary and multispeciality assessment and management may be most beneficial for individual patients. ➤ Therapeutic decisions need to be individualized and are made jointly by the patient and their clinician. Treatment should reflect patient preferences, with patients being provided with the best information concerning relevant options. Treatment choices may be affected by various factors, including disease activity, previous therapies, prognostic factors such as structural damage, comorbid conditions and patient factors such as cost, convenience and choice. ➤ Ideally, patients should be reviewed promptly, offered regular evaluation by appropriate specialists, and have treatment adjusted as needed in order to achieve the goals of therapy. Early diagnosis and treatment is likely to be of benefit.

Articles in this issue

Archives of this issue

view archives of GRAPPA Psoriatic Arthritis Recommendations 2021 - Novartis Translations - GRAPPA PsA Pocket Guide (English)